Axogen delivered strong Q4 2025 revenue growth of 21.3% year-over-year, driven by broad-based performance across all market segments. The quarter was highlighted by the landmark FDA BLA approval of Avance®, though net income was impacted by one-time costs related to this milestone.

Axogen, Inc. delivered a robust third quarter in 2025, with revenue reaching $60.1 million, marking a 23.5% increase year-over-year. The company achieved net income of $0.7 million and adjusted EBITDA of $9.2 million, demonstrating strong operational performance and profitability. Growth was broad-based across all key market segments, and the company raised its full-year revenue guidance.

Axogen, Inc. delivered a robust second quarter in 2025, achieving $56.7 million in revenue, an 18.3% increase year-over-year. The company reported a net income of $0.6 million, a significant improvement from a net loss in the prior year, and saw strong growth in adjusted EBITDA and gross margin.

Axogen, Inc. reported strong revenue growth in the first quarter of 2025, increasing by 17.4% year-over-year. Despite a decrease in gross margin due to increased product costs and inventory write-offs, the company saw improvements in both GAAP and non-GAAP net loss and adjusted EBITDA compared to the prior year. The company also made significant progress towards the anticipated BLA approval for Avance Nerve Graft.

Axogen, Inc. reported a 15.1% increase in fourth-quarter revenue, reaching $49.4 million. The company's net income for the quarter was $0.4 million, or $0.01 per share, compared to a net loss in the same quarter of the previous year. Adjusted EBITDA was $6.7 million, a significant increase from $0.6 million in Q4 2023.

Axogen reported a 17.9% increase in revenue to $48.6 million for the third quarter of 2024, with adjusted net income of $3.1 million, or $0.07 per share, and adjusted EBITDA of $6.5 million. The FDA accepted the filing of its Biologics License Application (BLA) for Avance Nerve Graft® under a standard review and assigned a PDUFA goal date of September 5th, 2025.

Axogen reported a strong second quarter with a 25.6% increase in revenue compared to the prior year. The company is progressing with its BLA submission for Avance Nerve Graft and saw positive trends in surgeon adoption of Avive+ Soft Tissue Matrix™.

Axogen, Inc. reported a 12.9% increase in first-quarter revenue, reaching $41.4 million compared to the previous year. The company's gross margin improved to 78.8%, and it reduced its net loss to $6.6 million, or $0.15 per share. The company is focused on higher productivity to reach profitability and positive cashflow.

Axogen reported an 18.7% increase in revenue for the fourth quarter, driven by growth in both emergent trauma and scheduled non-trauma procedures. The company is focused on expanding its leadership in nerve repair with the upcoming launch of Avive+ Soft Tissue Matrix and is progressing towards BLA submission for potential approval in mid-2025.

Axogen reported a 12% increase in revenue to $41.3 million for the third quarter of 2023, driven by both emergent trauma and scheduled non-trauma procedures. The company is maintaining its full-year 2023 revenue guidance in the range of $154 million to $159 million.

Axogen reported an 11% increase in revenue to $38.2 million for the second quarter of 2023 compared to the same period in 2022. The company experienced a net loss of $6.7 million, an improvement from the $7.7 million net loss in the second quarter of 2022. The company maintains full-year 2023 revenue guidance in the range of $154 million to $159 million.

Axogen reported a net revenue of $36.7 million, an 18% increase over the first quarter of 2022. The company's gross margin was 81.7%. Net loss was $7.1 million, or $0.17 per share, while adjusted net loss was $4.1 million, or $0.10 per share.

Axogen, Inc. reported a 17% increase in revenue for the fourth quarter of 2022, reaching $36.2 million. The company's gross margin remained strong at 83.0%. The net loss for the quarter was $5.4 million, or $0.13 per share, while the adjusted net loss was $1.1 million, or $0.03 per share.

Axogen reported a revenue increase of 18% compared to the third quarter of 2021, with a net loss of $4.3 million, an improvement from the previous year's $7.1 million loss. Adjusted EBITDA was $0.4 million, compared to a $2.5 million loss in the same quarter last year. The company is narrowing its full-year revenue guidance to $137.5 million to $140.0 million.

Axogen reported a 3% increase in net revenue to $34.5 million for the second quarter of 2022 compared to the second quarter of 2021. Excluding Avive revenue from the prior year, revenue increased by 9%. The gross margin improved to 81.8%, and the adjusted net loss decreased to $2.6 million, or $0.06 per share.

Axogen, Inc. reported first quarter 2022 financial results with net revenue of $31.0 million, matching the first quarter of 2021. Excluding Avive revenue from the previous year, revenue increased by 6%. The company's adjusted net loss was $8.5 million, or $0.20 per share, and the adjusted EBITDA loss was $7.4 million.

Axogen reported a slight decrease in revenue for Q4 2021 compared to the previous year, but showed improvements in gross margin. The company is focused on expanding its core accounts and is looking forward to the results of its RECON study.

Axogen, Inc. reported a 7% decrease in net revenue to $31.2 million compared to Q3 2020. The company's net loss was $7.1 million, or $0.17 per share, and the adjusted EBITDA loss was $2.5 million. Management is revising financial guidance, expecting full-year 2021 revenue will be in the range of $127.0 million to $129.0 million.

Axogen, Inc. reported a 52% increase in net revenue to $33.6 million for the second quarter of 2021, compared to $22.1 million in the second quarter of 2020. The company's gross margin improved to 78.9%, and the net loss was $7.9 million, or $0.19 per share.

Axogen, Inc. reported first quarter 2021 financial results with a 28% increase in net revenue to $31.0 million compared to the first quarter of 2020. The company's gross margin was 83.3%, and the net loss was $6.7 million, or $0.16 per share.

Axogen reported a revenue of $32.5 million for the quarter, a 15% increase compared to Q4 2019. The net loss for the quarter was $6.0 million, an improvement from the $7.0 million net loss in Q4 2019.

Axogen reported a 17% increase in net revenue to $33.4 million, with a gross margin of 83.0%. The company achieved adjusted net income of $1.5 million, or $0.04 per share, and an adjusted EBITDA of $2.3 million, marking a significant improvement compared to the previous year. The company ended the quarter with $106.7 million in cash, cash equivalents, and investments.

Axogen reported a decrease in net revenue by 17% compared to Q2 2019, with a net loss of $8.1 million. The company secured a new financing agreement for up to $75 million and saw an increase in cash, cash equivalents, and investments to $109.9 million.

Axogen reported a 4% increase in revenue compared to Q1 2019, but experienced a net loss of $8.2 million. The company's performance was negatively affected by the COVID-19 pandemic in March, leading to resource reallocation by customers and reduced traumatic injuries due to shelter-in-place orders. Axogen is implementing cost mitigation measures to address the impact of the pandemic.

Axogen, Inc. reported solid revenue growth in Q4 2019, with net sales increasing by 20% compared to the same quarter in 2018. However, the company's net loss also increased during the quarter. The company is focused on rebalancing its commercial operation toward extremity trauma.